Cruz-Bautista I

Idioma: Inglés [English version]
Referencias bibliográficas: 16
Paginas: s236-241
Archivo PDF: 305.56 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37: 2999-3058.

2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-188.

3. Huerta-Chagoya A, Moreno-Macías H, Sevilla-González M, Rodríguez-Guillén R, Ordóñez-Sánchez ML, Gómez-Velasco D et al. Contribution of known genetic risk variants to dyslipidemias and type 2 diabetes in Mexico: a population-based nationwide study. Genes (Basel). 2020; 11: 114.

4. Simha V. Management of hypertriglyceridemia. BMJ. 2020; 371: m3109.

5. Langsted A, Madsen CM, Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk. J Intern Med. 2020; 288: 116-127.

6. Salinas CAA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol. 2020; 31: 132-139.

7. Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020; 31: 140-146.

8. Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum HP et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFL. Atherosclerosis. 2020; 294: 46-61.

9. Duran EK, Pradhan AD. Triglyceride-Rich Lipoprotein remnants and cardiovascular disease. Clin Chem. 2021; 67: 183-196.

10. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41: 2313-2330.

11. Bjornson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S et al. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. J Intern Med. 2019; 285: 562-577.

12. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. On behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European. Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994; 110: 121-161.

13. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020; 41: 99-109.

14. Packard CJ, Borén J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020; 11: 252.

15. Cruz-Bautista I, Huerta-Chagoya A, Moreno-Macías H, Rodríguez-Guillén R, Ordóñez-Sánchez ML, Segura-Kato Y et al. Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia. Lipids Health Dis. 2021; 20: 14.

16. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015; 3: 339-355.